𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma

✍ Scribed by Frank V. Fossella; Rodger J. Winn; Paul Y. Holoye; Becky Hallinan; Martin N. Raber; Karen Hoelzer; James A. Young; Joseph Readling; Barbara Bowers; Waun Ki Hong

Publisher
Springer US
Year
1992
Tongue
English
Weight
368 KB
Volume
10
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of 4β€² deoxydoxorubicin (D
Phase II trial of 4β€² deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma
✍ Christopher Rose; Thomas E. Lad; Lary J. Kilton; Joel Schor; Steven T. Rosen; Ar πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 162 KB

A phase II trial of 4' Deoxydoxorubicin (DXDX) was conducted in unresectable previously untreated non-small cell lung cancer patients. DXDX was administered every 3 weeks by short intravenous infusion at a starting dose of 30 mg/m2, with dose escalation to 40 mg/m2 toxicity permitting. Four response

Weekly paclitaxel and gemcitabine chemot
Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC) : A dose-optimizing phase II trial
✍ Vera Hirsh; Renaud Whittom; Linda Ofiara; Pierre Desjardins; Joseph Ayoub; Danie πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The current dose‐optimizing Phase II study evaluated the effect of weekly paclitaxel and gemcitabine on the response rate and survival of patients with non‐small cell lung carcinoma (NSCLC) using dose modifications that permitted optimal treatment intensity. ## METHODS